Merck’s Combination Cholesterol Drug Liptruzet Gets FDA Nod

by Savitha C Muppala on May 9 2013 11:52 AM

 Merck’s Combination Cholesterol Drug Liptruzet Gets FDA Nod
New combination cholesterol drug, Liptruzet by Merck, has received approval by FDA. This drug helps in lowering a patient’s low-density lipoprotein (LDL) cholesterol levels.
This drug is a mix of drugs ezetimibe and atorvastatin and works well in the treatment of hyperlipidemia.

The FDA has approved the use of this drug to treat elevated LDL levels especially in cases where diet and lifestyle changes have not helped in making a difference to “bad cholesterol” levels.

The company said this combination pill is a boon for patients whose earlier attempts at lowering cholesterol had not worked. The dosage for the drug is usually one per day with a dosage range of 10/10 mg/day through 10/80 mg/day. Liptruzet may cost $5.50 per pill as per the list price of the company.

Every 1% reduction in your cholesterol level lowers your risk of heart disease by 2%. Each increase of 1 mg/dL (not percent) of your good cholesterol decreases your risk 2-3%.